目次

Table of Content

1. Overview Of DNA Cancer Vaccines
1.1 What Are DNA Cancer Vaccines?
1.2 History and Development Timeline
1.3 Comparison With Other Cancer Immunotherapies
1.4 Advantages and Limitations

2. DNA Cancer Vaccines - Mechanism of Action
2.1 How DNA Vaccines Work
2.2 Antigen Selection and Delivery
2.3 Role Of Vectors and Adjuvants
2.4 Immune Activation Pathways

3. Global DNA Cancer Vaccines - Recent Innovations

4. Global DNA Cancer Vaccines Market Overview
4.1 Current Market Scenario
4.2 Future Opportunity Outlook

5. DNA Cancer Vaccine Development Trends By Indication
5.1 Prostate Cancer
5.2 Cervical Cancer
5.3 Lung Cancer
5.4 Melanoma
5.5 Breast Cancer

6. DNA Cancer Vaccine Development Technology Platforms

7. Global DNA Cancer Vaccines Clinical Trials Overview
7.1 By Company
7.2 By Indication
7.3 By Phase

8. Global DNA Cancer Vaccines Clinical Trial Insight By Company, Indication and Phase
8.1 Preclinical
8.2 Phase I
8.3 Phase I/II
8.4 Phase II
8.5 Phase III

9. Global DNA Cancer Vaccines Market Dynamics
9.1 Growth Drivers and Opportunities
9.2 Market Restraints and Solutions

10. Competitive Landscape
10.1 4basebio
10.2 Aston Sci
10.3 Genexine
10.4 Evaxion
10.5 Immunomic Therapeutics
10.6 INOVIO
10.7 Madison Vaccines
10.8 Nykode Therapeutics
10.9 PapiVax Biotech
10.10 Takis

List of Figures & Tables
Figure 1-1: DNA Cancer Vaccines - Mechanism
Figure 1-2: DNA Cancer Vaccine - Milestones
Figure 1-3: DNA Cancer Vaccines - Safety Profile
Figure 1-4: DNA Vaccines vs. Other Immunotherapies - Durability Of Response
Figure 1-5: DNA Vaccine Delivery Methods
Figure 1-6: DNA Vaccine Immunogenicity - Challenges
Figure 2-1: DNA Vaccine Immune Response
Figure 2-2: DNA Vaccine - Antigen Presentation To Immune System
Figure 2-3: DNA Cancer Vaccine - Final Immune Response
Figure 2-4: Types Of Tumor Antigens
Figure 2-5: Challenges with Antigen Selection
Figure 2-6: Plasmid Vectors
Figure 2-7: Bacterial Vectors
Figure 2-8: Viral Vectors
Figure 2-9: Adjuvants In DNA Cancer Vaccines
Figure 2-10: New Developments In Adjuvants
Figure 2-11: DNA Sensors and Their Roles in Immune Activation
Figure 3-1: DoriVac DNA Vaccine Mechanism
Figure 3-2: andmu;EPO System - Key Features and Breakthroughs
Figure 3-3: Neomatrix Biotech: Revolutionizing Personalized Cancer Immunotherapy
Figure 4-1: Global DNA Cancer Vaccines Market - Future Opportunities
Figure 5-1: UW18037 Phase 2 (NCT04090528) Study - Initiation and Completion Year
Figure 5-2: UW25025 Phase 1 (NCT07090148) Study - Initiation and Completion Year
Figure 5-3: UW18008 Phase 2 (NCT03600350) Study - Initiation and Completion Year
Figure 5-4: J23105sIRB Phase 1 (NCT06315257) Study - Initiation and Completion Year
Figure 5-5: J1955 Phase 2 (NCT04131413) Study - Initiation and Completion Year
Figure 5-6: BB IND 18340 Phase 1 (NCT03913117) Study - Initiation and Completion Year
Figure 5-7: NEWISH-HPV-101 Phase 1 (NCT06276101) Study - Initiation and Completion Year
Figure 5-8: 202104143 Phase 2 (NCT04397003) Study - Initiation and Completion Year
Figure 5-9: NCI-2021-14159 Phase 2 (NCT05242965) Study - Initiation and Completion Year
Figure 5-10: SCOPE Phase 2 (NCT04079166) Study - Initiation and Completion Year
Figure 5-11: SCOPE Phase 2 (NCT04079166) Study - Initiation and Completion Year
Figure 5-12: SCOPE Phase 2 (NCT04079166) Study - Initiation and Completion Year
Figure 5-13: W81XWH-15-1-0101 Phase 1 (NCT02204098) Study - Initiation and Completion Year
Figure 5-14: NCI-2014-01070 Phase 1 (NCT02157051) Study - Initiation and Completion Year
Figure 5-15: NCI-2025-04692 Phase 2 (NCT07112053) Study - Initiation and Completion Year
Figure 5-16: NCI-2020-01662 Phase 2 (NCT04329065) Study - Initiation and Completion Year
Figure 5-17: NECVAX-NEO1-05-DE Phase 1/2 (NCT06631092) Study - Initiation and Completion Year
Figure 6-1: Enzymatic manufacturing process
Figure 6-2: Genexine - DNA Vaccine Platform
Figure 6-3: MVI Technology - DNA Plasmid Mechanism Of Action
Figure 6-4: Nykode - Protein Format
Figure 6-5: Nykode Therapeutics - DNA Vaccine Mechanism Of Action
Figure 6-6: DNA Medicines Technology - INOVIO
Figure 6-7: UNITE - Mode Of Action
Figure 6-8: GT-EPIC Platform - Process
Figure 6-9: LineaDNA - Production Process
Figure 6-10: GeneOne DNA Plasmid Technology - Principle
Figure 6-11: Fusogenix - FAST Protein Structure
Figure 6-12: PLV Technology
Figure 6-13: PLV Technology - Delivery Mechanism
Figure 7-1: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Company , 2025 -2026
Figure 7-2: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Indication (Numbers), 2025 -2026
Figure 7-3: Global - Number Of DNA Cancer Vaccines Clinical Pipeline by Phase (Numbers), 2025 - 2026
Figure 9-1: Global DNA Cancer Vaccines Market - Drivers and Opportunities
Figure 9-2: Global DNA Cancer Vaccines Market - Restraints and Solutions
Table 1-1: DNA Cancer Vaccines - Delivery Methods
Table 1-2: DNA Vaccine Platforms - Comparison
Table 1-3: DNA Cancer Vaccines - Comparison With Other Immunotherapies
Table 1-4: DNA Cancer Vaccines vs. mRNA Vaccines
Table 1-5: DNA Cancer Vaccines - Scalability and Manufacturing
Table 1-6: DNA Cancer Vaccines - Advantages
Table 6-1: LineaDNA - At A Glace